Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

6 novembre 2026 aggiornato da: Novartis Pharmaceuticals

Uno studio randomizzato, in doppio cieco, double-dummy, a gruppi paralleli, che confronta l'efficacia e la sicurezza di remibrutinib rispetto a teriflunomide nei partecipanti con sclerosi multipla recidivante, seguito da un trattamento esteso con remibrutinib in aperto

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.

The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).

The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.

A second study of identical design (CLOU064C12301) will be conducted simultaneously. Both studies will be conducted globally and data from the two studies will be pooled for some of the endpoints.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

1007

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Buenos Aires, Argentina, C1012AAR
        • Novartis Investigative Site
      • CABA, Argentina, C1181ACH
        • Novartis Investigative Site
      • Córdoba, Argentina, X5004CDT
        • Novartis Investigative Site
    • Mendoza Province
      • Bombal, Mendoza Province, Argentina, M5500DXO
        • Novartis Investigative Site
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000BZL
        • Novartis Investigative Site
      • Rosario, Santa Fe Province, Argentina, S2000DSW
        • Novartis Investigative Site
    • Tucumán Province
      • San Miguel de, Tucumán Province, Argentina, T4000
        • Novartis Investigative Site
      • São Paulo, Brasile, 01240-020
        • Novartis Investigative Site
    • Espírito Santo
      • Vitória, Espírito Santo, Brasile, 29055-450
        • Novartis Investigative Site
    • Federal District
      • Brasília, Federal District, Brasile, 70200-730
        • Novartis Investigative Site
    • Paraná
      • Curitiba, Paraná, Brasile, 81210-310
        • Novartis Investigative Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasile, 90430-001
        • Novartis Investigative Site
      • Porto Alegre, Rio Grande do Sul, Brasile, 90560-032
        • Novartis Investigative Site
      • Porto Alegre, Rio Grande do Sul, Brasile, 90620-130
        • Novartis Investigative Site
    • Santa Catarina
      • Joinville, Santa Catarina, Brasile, 89202-165
        • Novartis Investigative Site
      • Plovdiv, Bulgaria, 4002
        • Novartis Investigative Site
      • Sofia, Bulgaria, 1309
        • Novartis Investigative Site
      • Sofia, Bulgaria, 1431
        • Novartis Investigative Site
      • Sofia, Bulgaria, 1407
        • Novartis Investigative Site
    • Alberta
      • Edmonton, Alberta, Canada, T6G 2B7
        • Novartis Investigative Site
    • British Columbia
      • Burnaby, British Columbia, Canada, V5G 2X6
        • Novartis Investigative Site
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 4K4
        • Novartis Investigative Site
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Novartis Investigative Site
    • Quebec
      • Lévis, Quebec, Canada, G6W 0M5
        • Novartis Investigative Site
      • Montreal, Quebec, Canada, H4A 3T2
        • Novartis Investigative Site
      • Québec, Quebec, Canada, G1J 1Z4
        • Novartis Investigative Site
      • Saint-Jérôme, Quebec, Canada, J7Z 5T3
        • Novartis Investigative Site
      • Brno, Cechia, 602 00
        • Novartis Investigative Site
      • Hradec Králové, Cechia, 500 05
        • Novartis Investigative Site
      • Teplice, Cechia, 415 29
        • Novartis Investigative Site
      • Beijing, Cina, 100034
        • Novartis Investigative Site
      • Shanghai, Cina, 200025
        • Novartis Investigative Site
      • Shanghai, Cina, 200040
        • Novartis Investigative Site
    • Hubei
      • Wuhan, Hubei, Cina, 430030
        • Novartis Investigative Site
      • Wuhan, Hubei, Cina, 430060
        • Novartis Investigative Site
    • Jiangsu
      • Nanjing, Jiangsu, Cina, 210029
        • Novartis Investigative Site
    • Ningxia
      • Yinchuan, Ningxia, Cina, 750004
        • Novartis Investigative Site
    • Shanxi
      • Taiyuan, Shanxi, Cina, 030001
        • Novartis Investigative Site
    • Zhejiang
      • Hangzhou, Zhejiang, Cina, 310016
        • Novartis Investigative Site
      • Hangzhou, Zhejiang, Cina, 310006
        • Novartis Investigative Site
      • Wenzhou, Zhejiang, Cina, 325000
        • Novartis Investigative Site
      • Zagreb, Croazia, 10000
        • Novartis Investigative Site
    • Croatia
      • Zagreb, Croatia, Croazia, 10000
        • Novartis Investigative Site
    • HRV
      • Split, HRV, Croazia, 21000
        • Novartis Investigative Site
      • Varaždin, HRV, Croazia, 42000
        • Novartis Investigative Site
    • Vukovar
      • Vukovar, Vukovar, Croazia, 32000
        • Novartis Investigative Site
      • Tallinn, Estonia, 11315
        • Novartis Investigative Site
      • Tartu, Estonia, 50406
        • Novartis Investigative Site
      • Caen, Francia, 14033
        • Novartis Investigative Site
      • Clermont-Ferrand, Francia, 63003
        • Novartis Investigative Site
      • Dijon, Francia, 21000
        • Novartis Investigative Site
      • Gonesse, Francia, 95500
        • Novartis Investigative Site
      • Grenoble, Francia, 38043
        • Novartis Investigative Site
      • Lille, Francia, 59037
        • Novartis Investigative Site
      • Lille, Francia, 59000
        • Novartis Investigative Site
      • Nice, Francia, 06000
        • Novartis Investigative Site
      • Nîmes, Francia, 30029
        • Novartis Investigative Site
      • Poissy, Francia, 78303
        • Novartis Investigative Site
      • Toulouse, Francia, 31059
        • Novartis Investigative Site
    • Haute Vienne
      • Limoges, Haute Vienne, Francia, 87000
        • Novartis Investigative Site
    • Val De Marne
      • Toulon, Val De Marne, Francia, 83800
        • Novartis Investigative Site
      • Essen, Germania, 45147
        • Novartis Investigative Site
      • Hamburg, Germania, 22179
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, Germania, 79106
        • Novartis Investigative Site
      • Fukuoka, Giappone, 8128582
        • Novartis Investigative Site
      • Niigata, Giappone, 9518520
        • Novartis Investigative Site
    • Aichi-ken
      • Nagoya, Aichi-ken, Giappone, 4668560
        • Novartis Investigative Site
    • Chiba
      • Chiba, Chiba, Giappone, 2608677
        • Novartis Investigative Site
      • Ichihara, Chiba, Giappone, 2990111
        • Novartis Investigative Site
    • Fukuoka
      • Fukuoka, Fukuoka, Giappone, 8100022
        • Novartis Investigative Site
    • Hokkaido
      • Sapporo, Hokkaido, Giappone, 0630005
        • Novartis Investigative Site
    • Hyōgo
      • Kobe, Hyōgo, Giappone, 6500017
        • Novartis Investigative Site
      • Nishinomiya, Hyōgo, Giappone, 663 8501
        • Novartis Investigative Site
    • Kanagawa
      • Isehara, Kanagawa, Giappone, 2591193
        • Novartis Investigative Site
      • Sagamihara, Kanagawa, Giappone, 2520375
        • Novartis Investigative Site
    • Kyoto
      • Kyoto, Kyoto, Giappone, 6168255
        • Novartis Investigative Site
    • Miyagi
      • Sendai, Miyagi, Giappone, 9838512
        • Novartis Investigative Site
    • Nara
      • Kashihara, Nara, Giappone, 6348522
        • Novartis Investigative Site
    • Osaka
      • Moriguchi, Osaka, Giappone, 5708507
        • Novartis Investigative Site
      • Suita, Osaka, Giappone, 5650871
        • Novartis Investigative Site
    • Saitama
      • Higashi-Matsuyama, Saitama, Giappone, 3550005
        • Novartis Investigative Site
    • Tokyo
      • Kodaira, Tokyo, Giappone, 1878551
        • Novartis Investigative Site
      • Shinjuku Ku, Tokyo, Giappone, 1628666
        • Novartis Investigative Site
      • Shinjuku Ku, Tokyo, Giappone, 1600023
        • Novartis Investigative Site
      • Shinjuku-ku, Tokyo, Giappone, 1608582
        • Novartis Investigative Site
      • tabashi City, Tokyo, Giappone, 1738610
        • Novartis Investigative Site
      • Athens, Grecia, 115 28
        • Novartis Investigative Site
      • Athens, Grecia, 115 26
        • Novartis Investigative Site
      • Chaïdári, Grecia, 124 62
        • Novartis Investigative Site
      • Ioannina, Grecia, 455 00
        • Novartis Investigative Site
      • Larissa, Grecia, 411 10
        • Novartis Investigative Site
      • Thessaloniki, Grecia, 532 46
        • Novartis Investigative Site
      • Thessaloniki, Grecia, 546 36
        • Novartis Investigative Site
    • Kerala
      • Kochi, Kerala, India, 682025
        • Novartis Investigative Site
    • Maharashtra
      • Pune, Maharashtra, India, 411013
        • Novartis Investigative Site
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, India, 110060
        • Novartis Investigative Site
    • Punjab
      • Amritsar, Punjab, India, 143006
        • Novartis Investigative Site
    • Telangana
      • Hyderabad, Telangana, India, 500082
        • Novartis Investigative Site
    • Uttar Pradesh
      • Lucknow, Uttar Pradesh, India, 226007
        • Novartis Investigative Site
    • West Bengal
      • Kolkata, West Bengal, India, 700017
        • Novartis Investigative Site
      • Naples, Italia, 80138
        • Novartis Investigative Site
    • BR
      • Brindisi, BR, Italia, 72100
        • Novartis Investigative Site
    • FG
      • Foggia, FG, Italia, 71122
        • Novartis Investigative Site
    • IS
      • Pozzilli, IS, Italia, 86077
        • Novartis Investigative Site
    • ME
      • Messina, ME, Italia, 98124
        • Novartis Investigative Site
    • MO
      • Modena, MO, Italia, 41126
        • Novartis Investigative Site
    • PV
      • Pavia, PV, Italia, 27100
        • Novartis Investigative Site
    • TO
      • Orbassano, TO, Italia, 10043
        • Novartis Investigative Site
      • Mexico City, Messico, 14050
        • Novartis Investigative Site
      • Querétaro, Messico, 76070
        • Novartis Investigative Site
    • Chihuahua
      • Chihuahua City, Chihuahua, Messico, 31203
        • Novartis Investigative Site
    • Mexico City
      • Mexico City, Mexico City, Messico, 06700
        • Novartis Investigative Site
      • Bialystok, Polonia, 15-704
        • Novartis Investigative Site
      • Glogow Wielkopolski, Polonia, 36-060
        • Novartis Investigative Site
      • Katowice, Polonia, 40-081
        • Novartis Investigative Site
      • Katowice, Polonia, 40-571
        • Novartis Investigative Site
      • Katowice, Polonia, 40-686
        • Novartis Investigative Site
      • Katowice, Polonia, 40-689
        • Novartis Investigative Site
      • Lublin, Polonia, 20-701
        • Novartis Investigative Site
      • Wroclaw, Polonia, 51-685
        • Novartis Investigative Site
      • Zabrze, Polonia, 41-800
        • Novartis Investigative Site
    • Poznan
      • Plewiska, Poznan, Polonia, 62-064
        • Novartis Investigative Site
      • Guaynabo, Porto Rico, 00968
        • Caribbean Center for Clinical Research Inc
      • Braga, Portogallo, 4710-243
        • Novartis Investigative Site
      • Coimbra, Portogallo, 3004-561
        • Novartis Investigative Site
      • Leiria, Portogallo, 2410-197
        • Novartis Investigative Site
      • Lisbon, Portogallo, 1649-035
        • Novartis Investigative Site
      • Lisbon, Portogallo, 1169-050
        • Novartis Investigative Site
      • Matosinhos Municipality, Portogallo, 4454-513
        • Novartis Investigative Site
      • Santa Maria da Feira, Portogallo, 4520-211
        • Novartis Investigative Site
    • Invernesshire
      • Inverness, Invernesshire, Regno Unito, IV2 3RE
        • Novartis Investigative Site
    • Kent
      • Canterbury, Kent, Regno Unito, CT1 3NG
        • Novartis Investigative Site
      • Campulung Muscel, Romania, 115100
        • Novartis Investigative Site
      • Constanța, Romania, 900591
        • Novartis Investigative Site
    • ROM
      • Brasov, ROM, Romania, 500123
        • Novartis Investigative Site
      • Constanța, ROM, Romania, 900123
        • Novartis Investigative Site
      • Banská Bystrica, Slovacchia, 975 17
        • Novartis Investigative Site
      • Banská Bystrica, Slovacchia, 974 04
        • Novartis Investigative Site
      • Bratislava, Slovacchia, 833 05
        • Novartis Investigative Site
      • Celje, Slovenia, 3000
        • Novartis Investigative Site
      • Ljubljana, Slovenia, 1000
        • Novartis Investigative Site
    • Slovenia
      • Maribor, Slovenia, Slovenia, 2000
        • Novartis Investigative Site
      • Lleida, Spagna, 25198
        • Novartis Investigative Site
      • Madrid, Spagna, 28040
        • Novartis Investigative Site
      • Madrid, Spagna, 28009
        • Novartis Investigative Site
      • Málaga, Spagna, 29016
        • Novartis Investigative Site
      • Seville, Spagna, 41009
        • Novartis Investigative Site
      • Valencia, Spagna, 46026
        • Novartis Investigative Site
    • A Coruna
      • Santiago Compostela, A Coruna, Spagna, 15706
        • Novartis Investigative Site
    • Araba
      • Vitoria-Gasteiz, Araba, Spagna, 01009
        • Novartis Investigative Site
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Spagna, 08907
        • Novartis Investigative Site
    • Castille-La Mancha
      • Albacete, Castille-La Mancha, Spagna, 02006
        • Novartis Investigative Site
    • Catalonia
      • Barcelona, Catalonia, Spagna, 08003
        • Novartis Investigative Site
    • La Rioja
      • Logroño, La Rioja, Spagna, 26006
        • Novartis Investigative Site
    • Madrid
      • Pozuelo de Alarcón, Madrid, Spagna, 28223
        • Novartis Investigative Site
      • Torrejón de Ardoz, Madrid, Spagna, 28850
        • Novartis Investigative Site
    • Principality of Asturias
      • Gijón, Principality of Asturias, Spagna, 33394
        • Novartis Investigative Site
    • Valencia
      • Valencia, Valencia, Spagna, 46017
        • Novartis Investigative Site
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85018
        • Ctr for Neurology and Spine
    • California
      • Hanford, California, Stati Uniti, 93230
        • Vladimir Royter MD APMC
      • Los Angeles, California, Stati Uniti, 90073
        • VA Greater LA Healthcare System
      • West Hollywood, California, Stati Uniti, 90048
        • Regina Berkovich MD PhD Inc
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • CU Anschutz Med Campus
      • Denver, Colorado, Stati Uniti, 80210
        • Colorado Neurological Research PC
    • Connecticut
      • Stamford, Connecticut, Stati Uniti, 06905
        • New England Institute for Clinical Research
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20007
        • Georgetown University Hospital
      • Washington D.C., District of Columbia, Stati Uniti, 20007
        • Georgetown University Hospital Research
    • Florida
      • Bradenton, Florida, Stati Uniti, 34209
        • Nova Clinical Research LLC
      • Gainesville, Florida, Stati Uniti, 32610
        • University of Florida
      • Hollywood, Florida, Stati Uniti, 33021
        • Memorial Healthcare System
      • Maitland, Florida, Stati Uniti, 32751
        • Neurology Associates PA
      • Miami, Florida, Stati Uniti, 33136
        • UM Department Of Neurology
      • Miami, Florida, Stati Uniti, 33133
        • Gables Neurology
      • Naples, Florida, Stati Uniti, 34105
        • Aqualane Clinical Research
      • Orlando, Florida, Stati Uniti, 32803
        • Advent Health Orlando
      • Pembroke Pines, Florida, Stati Uniti, 33024
        • Humanity Clinical Research
      • Pensacola, Florida, Stati Uniti, 32514
        • Emerald Coast Neurology
      • Port Orange, Florida, Stati Uniti, 32127
        • Brain and Spine Institute
      • Vero Beach, Florida, Stati Uniti, 32960
        • Vero Beach Neurology
      • Winter Park, Florida, Stati Uniti, 32789
        • Conquest Research
    • Indiana
      • Merrillville, Indiana, Stati Uniti, 46410
        • Methodist Neuroscience Institute
    • Kansas
      • Kansas City, Kansas, Stati Uniti, 66160
        • University of Kansas Hospital
    • Kentucky
      • Nicholasville, Kentucky, Stati Uniti, 40356
        • Baptist Physicians Lexington
    • Louisiana
      • New Orleans, Louisiana, Stati Uniti, 70121
        • Ochsner Clinic Foundation
    • Maryland
      • Frederick, Maryland, Stati Uniti, 21702
        • Clinre Comprehensive Neurology
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02111
        • Tufts Medical Center
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64128
        • Kansas City VA Medical Center
    • New York
      • Patchogue, New York, Stati Uniti, 11772
        • South Shore Neurologic Associates
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27599-9500
        • University Of NC At Chapel Hill
      • Charlotte, North Carolina, Stati Uniti, 28210
        • Piedmont HealthCare
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43235
        • The Boster Ctr for MS
      • Dayton, Ohio, Stati Uniti, 45408
        • Neurology Diagnostics Inc
    • Pennsylvania
      • Hershey, Pennsylvania, Stati Uniti, 17033
        • Penn State Hershey Medical Center
    • South Carolina
      • Greenville, South Carolina, Stati Uniti, 29605
        • Premier Neurology
      • Old Point Station, South Carolina, Stati Uniti, 29707
        • Metrolina Neurological Associates PA
    • Tennessee
      • Knoxville, Tennessee, Stati Uniti, 37922
        • Sibyl Wray MD Neurology PC
    • Texas
      • Dallas, Texas, Stati Uniti, 75231
        • Carum Research
      • El Paso, Texas, Stati Uniti, 79935
        • Med Research Inc
      • Frisco, Texas, Stati Uniti, 75035
        • Lone Star Neurology
      • San Antonio, Texas, Stati Uniti, 78258
        • Lonestar Neurology of San Antonio
      • San Antonio, Texas, Stati Uniti, 78229
        • UT Health MARC Medical Arts and Research Center
      • Sherman, Texas, Stati Uniti, 75092
        • Texas Institute for Neurological Disorders
      • Temple, Texas, Stati Uniti, 76508
        • Baylor Scott and White
    • Washington
      • Seattle, Washington, Stati Uniti, 98101
        • Virginia Mason Medical Centre
      • Seattle, Washington, Stati Uniti, 98133
        • University of Washington MS Clinic
    • West Virginia
      • Crab Orchard, West Virginia, Stati Uniti, 25827
        • Elligo Health Research
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Medical College of Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53215
        • Ascension St Francis Center
      • Pretoria, Sud Africa, 0041
        • Novartis Investigative Site
      • Rosebank, Sud Africa, 2196
        • Novartis Investigative Site
    • Free State
      • Bloemfontein, Free State, Sud Africa, 9301
        • Novartis Investigative Site
      • Stockholm, Svezia, 102 35
        • Novartis Investigative Site
      • Konya, Turchia (Türkiye), 42130
        • Novartis Investigative Site
    • Atakum
      • Samsun, Atakum, Turchia (Türkiye), 55200
        • Novartis Investigative Site
    • Balcova
      • Izmir, Balcova, Turchia (Türkiye), 35340
        • Novartis Investigative Site
    • Fatih
      • Istanbul, Fatih, Turchia (Türkiye), 34098
        • Novartis Investigative Site
      • Istanbul, Fatih, Turchia (Türkiye), 34093
        • Novartis Investigative Site
    • Karabaglar
      • Izmir, Karabaglar, Turchia (Türkiye), 35150
        • Novartis Investigative Site
    • Kocaeli
      • Köseköy, Kocaeli, Turchia (Türkiye), 41380
        • Novartis Investigative Site
    • Melikgazi
      • Kayseri, Melikgazi, Turchia (Türkiye), 38039
        • Novartis Investigative Site
    • Nilufer
      • Bursa, Nilufer, Turchia (Türkiye), 16140
        • Novartis Investigative Site
    • Pendik
      • Istanbul, Pendik, Turchia (Türkiye), 34899
        • Novartis Investigative Site
    • Sancaktepe
      • Istanbul, Sancaktepe, Turchia (Türkiye), 34785
        • Novartis Investigative Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 55 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • 18 to 55 years of age
  • Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
  • At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
  • EDSS score of 0 to 5.5 (inclusive)
  • Neurologically stable within 1 month

Exclusion Criteria:

  • Diagnosis of primary progressive multiple sclerosis (PPMS)

  • Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening

  • History of clinically significant CNS disease other than MS

  • Ongoing substance abuse (drug or alcohol)

  • History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),

  • Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML

  • suicidal ideation or behavior

  • Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence

  • Participants who have had a splenectomy

  • Active clinically significant systemic bacterial, viral, parasitic or fungal infections

  • Positive results for syphilis or tuberculosis testing

  • Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids

  • Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.

  • Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody

  • History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis (including all Child-Pugh classes) or hepatic failure or any chronic liver or biliary disease.

  • History of severe renal disease or creatinine level

  • Participants at risk of developing or having reactivation of hepatitis

  • Hematology parameters at screening:

    • Hemoglobin: < 10 g/dl (<100g/L)
    • Platelets: < 100000/mm3 (<100 x 109/L)
    • Absolute lymphocyte count < 800/mm3 (<0.8 x 109/L)
    • White blood cells: <3 000/mm3 (<3.0 x 109/L)
    • Neutrophils: < 1 500/mm3 (<1.5 x 109/L)
    • B-cell count < 50% lower limit of normal (LLN) or total IgG & total IgM < LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
  • History or current diagnosis of significant ECG abnormalities

  • Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment as per central ECG reading at screening visit

  • Use of other investigational drugs

  • Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,

  • History of gastrointestinal bleeding

  • Major surgery within 8 weeks prior to screening

  • History of hypersensitivity to any of the study drugs or excipients

  • Pregnant or nursing (lactating) female participants, prior to randomization

  • Women of childbearing potential not using highly effective contraception

  • Sexually active males not agreeing to use condom

  • Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study

  • Use of strong CYP3A4 inhibitors or use of moderate or strong CYP3A4 inducers within two weeks prior to randomization

Inclusion to Extension part:

• Participants who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)

Other inclusion and exclusion criteria may apply.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Remibrutinib - Core

Remibrutinib tablet and matching placebo of teriflunomide capsule

tablet taken orally

Altri nomi:
  • LOU064
Comparatore attivo: Teriflunomide - Core

Teriflunomide capsule and matching placebo remibrutinib tablet

capsule taken orally

Sperimentale: Remibrutinib - Extension

Participants on remibrutinib in Core will continue on remibrutinib tablet

tablet taken orally

Altri nomi:
  • LOU064
Sperimentale: Remibrutinib - Extension (on teriflunomide in Core)

Participants on teriflunomide in Core will switch to remibrutinib tablet

tablet taken orally

Altri nomi:
  • LOU064

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Annualized relapse rate (ARR) of confirmed relapses [Core Part]
Lasso di tempo: From Baseline, up to 30 months

ARR is the average number of confirmed MS relapses in a year

From Baseline, up to 30 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS) [Core Part] (pooled data)
Lasso di tempo: Baseline up to 30 months

Time to 3-month confirmed disability progression (3mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months

Baseline up to 30 months
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Core Part] (pooled data)
Lasso di tempo: Baseline up to 30 months

Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months

Baseline up to 30 months
Annualized rate of new or enlarging T2 lesion [Core Part]
Lasso di tempo: Baseline up to 30 months

Number of new/newly enlarged T2 lesions per year

Baseline up to 30 months
Neurofilament light chain (Nfl) [Core Part]
Lasso di tempo: Baseline up to 30 months

Neurofilament light chain (NfL) concentration in serum

Baseline up to 30 months
Number of Gd-enhancing T1 lesions per MRI scan [Core Part]
Lasso di tempo: Baseline up to 30 months

Average number of Gd-enhancing T1 lesions per scan

Baseline up to 30 months
Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3) [Core Part] (pooled data)
Lasso di tempo: Baseline up to 30 months

Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6mCDP and new/enlarging T2 lesions on MRI

Baseline up to 30 months
Time to first confirmed relapse [Core Part]
Lasso di tempo: Baseline up to 30 months

Change in the Expanded Disability Status Scale (EDSS), an increase of at least 0.5 points on the EDSS (total) score, or an increase of at least 1 point on at least two functional scores (FSs), or an increase of at least 2 points on at least one FS, excluding changes involving bowel/bladder or cerebral FS, compared to the previous available rating.

Baseline up to 30 months
Time to 6-month confirmed disability improvement (6mCDI) on EDSS [Core Part] (pooled data)
Lasso di tempo: Baseline up to 30 months

Decrease in Expanded Disability Status Scale Score (EDSS) which is sustained for at least 6 months

Baseline up to 30 months
Time to 3-months confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) independent of relapse activity (PIRA) [Core Part] (pooled data)
Lasso di tempo: Baseline up to 30 months

Time to 3-month confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months or 6 months, respectively, without an on-study relapse before or on the day of a progression eve

Baseline up to 30 months
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Core Part] (pooled data)
Lasso di tempo: Baseline up to 30 months

Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening

Baseline up to 30 months
Time to 6-month confirmed worsening by at least 20% in the Timed 25-foot walk test (T25FW) [Core Part] (pooled data)
Lasso di tempo: Baseline, up to 30 months

The patient walking speed to cover 25-foot distance is recorded in seconds. Longer time indicates poorer lower limb function. 20% worsening is defined as 20% increase from baseline T25FW score

Baseline, up to 30 months
Time to 6-month confirmed worsening by at least 20% in the Timed 9-hole peg test (9HPT) (pooled data) [Core Part] (pooled data)
Lasso di tempo: Baseline up to 30 months

The patient's right and left arm function to peg 9 holes measured in seconds. Longer time indicates poorer upper limb function. 20% worsening is defined as 20% increase from baseline 9HPT score in at least one hand (average of two trials per hand)

Baseline up to 30 months
Time to composite 6-month confirmed disability Progression (CDP) [Core Part] (pooled data)
Lasso di tempo: Baseline up to 30 months

The composite involves CDP and worsening by at least 20% in T25FW and 9HPT

Baseline up to 30 months
Change from Baseline in T2 lesion volume [Core Part]
Lasso di tempo: Baseline up to 30 months

Change from baseline in total T2 lesion volume.

Baseline up to 30 months
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Core Part]
Lasso di tempo: Baseline up to 30 months

29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life

Baseline up to 30 months
Number of participants with Adverse events and Serious adverse events(SAE) [Core Part]
Lasso di tempo: Baseline up to 30 months

Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating

Baseline up to 30 months
Pharmacokinetics of remibrutinib [Core Part]
Lasso di tempo: Month 1, Month 6

Blood concentrations of remibrutinib

Month 1, Month 6
Number of participants with Adverse events and Serious adverse events (SAE) [Extension Part]
Lasso di tempo: Day 1 Extension up to 5 years

Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating

Day 1 Extension up to 5 years
Annualized relapse rate (ARR) of confirmed relapses [Extension Part]
Lasso di tempo: Day 1 Extension up to 5 years

ARR is the average number of confirmed MS relapses in a year

Day 1 Extension up to 5 years
Annualized rate of new or enlarging T2 lesion [Extension Part]
Lasso di tempo: Day 1 Extension up to 5 years

Number of new/newly enlarged T2 lesions per year

Day 1 Extension up to 5 years
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Extension Part]
Lasso di tempo: Day 1 Extension up to 5 years

Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months

Day 1 Extension up to 5 years
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Extension Part]
Lasso di tempo: Day 1 Extension up to 5 years

Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening

Day 1 Extension up to 5 years
Neurofilament light chain (NfL) [Extension Part]
Lasso di tempo: Day 1 Extension up to 5 years

Neurofilament light chain (NfL) concentration in serum

Day 1 Extension up to 5 years
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Extension Part]
Lasso di tempo: Day 1 Extension up to 5 years

29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life

Day 1 Extension up to 5 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

13 dicembre 2021

Completamento primario (Effettivo)

22 luglio 2026

Completamento dello studio (Stimato)

30 ottobre 2030

Date di iscrizione allo studio

Primo inviato

1 dicembre 2021

Primo inviato che soddisfa i criteri di controllo qualità

1 dicembre 2021

Primo Inserito (Effettivo)

14 dicembre 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CLOU064C12302
  • 2023-509372-41-00 (Identificatore di registro: EU CTIS)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .